Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) – Pipeline Review, H2 2016’, provides in depth analysis on Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1)

The report reviews Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Advenchen Laboratories, LLC

Amgen Inc.

ArQule, Inc.

Astellas Pharma Inc.

AstraZeneca Plc

AVEO Pharmaceuticals, Inc.

Batu Biologics, Inc.

Bayer AG

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Celon Pharma Sp. z o.o.

Daiichi Sankyo Company, Limited

Debiopharm International SA

Eddingpharm

Eisai Co., Ltd.

Eli Lilly and Company

Hutchison MediPharma Limited

Incyte Corporation

Johnson & Johnson

Kaken Pharmaceutical Co., Ltd.

Les Laboratoires Servier SAS

Nobelpharma Co., Ltd.

Novartis AG

Principia Biopharma Inc.

Vichem Chemie Research Ltd.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC

2.7.10.1) Overview 10

Therapeutics Development 11

Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC

2.7.10.1) - Products under Development by Stage of Development 11

Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC

2.7.10.1) - Products under Development by Therapy Area 12

Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC

2.7.10.1) - Products under Development by Indication 13

Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC

2.7.10.1) - Pipeline Products Glance 15

Late Stage Products 15

Early Stage Products 16

Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC

2.7.10.1) - Products under Development by Companies 17

Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC

2.7.10.1) - Products under Development by Universities/Institutes 25

Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC

2.7.10.1) - Therapeutics Assessment 27

Assessment by Monotherapy/Combination Products 27

Assessment by Mechanism of Action 28

Assessment by Route of Administration 30

Assessment by Molecule Type 32

Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC

2.7.10.1) - Companies Involved in Therapeutics Development 34

Advenchen Laboratories, LLC 34

Amgen Inc. 35

ArQule, Inc. 36

Astellas Pharma Inc. 37

AstraZeneca Plc 38

AVEO Pharmaceuticals, Inc. 39

Batu Biologics, Inc. 40

Bayer AG 41

Boehringer Ingelheim GmbH 42

Bristol-Myers Squibb Company 43

Celon Pharma Sp. z o.o. 44

Daiichi Sankyo Company, Limited 45

Debiopharm International SA 46

Eddingpharm 47

Eisai Co., Ltd. 48

Eli Lilly and Company 50

Hutchison MediPharma Limited 51

Incyte Corporation 52

Johnson & Johnson 53

Kaken Pharmaceutical Co., Ltd. 54

Les Laboratoires Servier SAS 55

Nobelpharma Co., Ltd. 56

Novartis AG 57

Principia Biopharma Inc. 58

Vichem Chemie Research Ltd. 59

Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC

2.7.10.1) - Drug Profiles 60

ARQ-087 - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

ASP-5878 - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

AZD-4547 - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

BAY-1163877 - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

BAY-1179470 - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

BMS-986036 - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

CPL-043 - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

Debio-1347 - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

DS-1123 - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

E-7090 - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

EDP-317 - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

erdafitinib - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

GP-369 - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

HMPL-453 - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

INCB-54828 - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

infigratinib - Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

L-27 - Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

lenvatinib mesylate - Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

lucitanib - Drug Profile 95

Product Description 95

Mechanism Of Action 95

R&D Progress 95

LY-2874455 - Drug Profile 98

Product Description 98

Mechanism Of Action 98

R&D Progress 98

nintedanib - Drug Profile 99

Product Description 99

Mechanism Of Action 99

R&D Progress 99

palifermin - Drug Profile 108

Product Description 108

Mechanism Of Action 108

R&D Progress 108

PRN-1371 - Drug Profile 109

Product Description 109

Mechanism Of Action 109

R&D Progress 109

Recombinant Protein to Agonize FGFR for Type 2 Diabetes - Drug Profile 110

Product Description 110

Mechanism Of Action 110

R&D Progress 110

Recombinant Proteins to Agonize FGFR for Metabolic Disorders - Drug Profile 111

Product Description 111

Mechanism Of Action 111

R&D Progress 111

RPT-835 - Drug Profile 112

Product Description 112

Mechanism Of Action 112

R&D Progress 112

S-49076 - Drug Profile 113

Product Description 113

Mechanism Of Action 113

R&D Progress 113

Small Molecules to Antagonize Pan FGFR for Oncology - Drug Profile 114

Product Description 114

Mechanism Of Action 114

R&D Progress 114

trafermin - Drug Profile 115

Product Description 115

Mechanism Of Action 115

R&D Progress 115

trafermin - Drug Profile 117

Product Description 117

Mechanism Of Action 117

R&D Progress 117

Vallovax - Drug Profile 118

Product Description 118

Mechanism Of Action 118

R&D Progress 118

Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC

2.7.10.1) - Dormant Projects 119

Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC

2.7.10.1) - Discontinued Products 122

Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC

2.7.10.1) - Featured News & Press Releases 124

Oct 26, 2016: Eisais LENVIMA (lenvatinib) Nominated for Galien Foundations Best Pharmaceutical Product 124

Oct 24, 2016: Efficacy of Ofev (nintedanib) Reinforced in Range of Patients with IPF in New Analyses Presented at CHEST 124

Oct 12, 2016: Preliminary Phase Ib Clinical Study Results for Lenvatinib in Combination with Pembrolizumab in Selected Solid Tumors Presented at ESMO 2016 125

Oct 09, 2016: ESMO 2016: Lenvatinib Shows Promising Activity in Patients with RET-Positive Adenocarcinoma of the Lung 127

Oct 09, 2016: People with an Advanced Form of Thyroid Cancer Now Able to Benefit From Lenvima (lenvatinib) in Scotland 128

Oct 09, 2016: Phase III nintedanib trial results in patients with metastatic colorectal cancer announced at ESMO 130

Oct 08, 2016: Phase I study of novel anti-cancer drug uses tumor mRNA expression to identify responders 130

Sep 30, 2016: Eisai To Initiate Phase III Clinical Study Of Anticancer Agent Lenvatinib As Potential First-Line Therapy For Advanced Renal Cell Carcinoma 131

Sep 29, 2016: Eisai To Present Latest Data On Lenvatinib At ESMO Congress 2016 132

Sep 28, 2016: Bayer presents New Data on BAY 1163877 at ESMO 2016 Congress 133

Sep 21, 2016: Eisai to Present Updates on Lenvatinib in Two Types of Thyroid Cancer at 86th Annual Meeting of the American Thyroid Association 134

Sep 15, 2016: Eisai Receives License For New Indication For Anticancer Agent Kisplyx (Lenvatinib Mesylate) For Treatment Of Advanced Renal Cell Carcinoma 135

Sep 15, 2016: ArQule Announces Publication of Manuscript Highlighting Preclinical Activity of FGFR Inhibitor, ARQ 087, in Peer Reviewed Journal 136

Sep 09, 2016: Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease 136

Sep 07, 2016: New long-term data demonstrates continued safety and beneficial effect of OFEV (nintedanib) for patients with IPF 137

Appendix 139

Methodology 139

Coverage 139

Secondary Research 139

Primary Research 139

Expert Panel Validation 139

Contact Us 139

Disclaimer 140

List of Tables

List of Tables

Number of Products under Development for, H2 2016 11

Number of Products under Development by Therapy Area, H2 2016 12

Number of Products under Development by Indication, H2 2016 13

Comparative Analysis by Late Stage Development, H2 2016 15

Comparative Analysis by Early Stage Products, H2 2016 16

Number of Products under Development by Companies, H2 2016 17

Products under Development by Companies, H2 2016 18

Products under Development by Companies, H2 2016 (Contd..1) 19

Products under Development by Companies, H2 2016 (Contd..2) 20

Products under Development by Companies, H2 2016 (Contd..3) 21

Products under Development by Companies, H2 2016 (Contd..4) 22

Products under Development by Companies, H2 2016 (Contd..5) 23

Products under Development by Companies, H2 2016 (Contd..6) 24

Number of Products under Investigation by Universities/Institutes, H2 2016 25

Products under Investigation by Universities/Institutes, H2 2016 26

Assessment by Monotherapy/Combination Products, H2 2016 27

Number of Products by Stage and Mechanism of Action, H2 2016 29

Number of Products by Stage and Route of Administration, H2 2016 31

Number of Products by Stage and Molecule Type, H2 2016 33

Pipeline by Advenchen Laboratories, LLC, H2 2016 34

Pipeline by Amgen Inc., H2 2016 35

Pipeline by ArQule, Inc., H2 2016 36

Pipeline by Astellas Pharma Inc., H2 2016 37

Pipeline by AstraZeneca Plc, H2 2016 38

Pipeline by AVEO Pharmaceuticals, Inc., H2 2016 39

Pipeline by Batu Biologics, Inc., H2 2016 40

Pipeline by Bayer AG, H2 2016 41

Pipeline by Boehringer Ingelheim GmbH, H2 2016 42

Pipeline by Bristol-Myers Squibb Company, H2 2016 43

Pipeline by Celon Pharma Sp. z o.o., H2 2016 44

Pipeline by Daiichi Sankyo Company, Limited, H2 2016 45

Pipeline by Debiopharm International SA, H2 2016 46

Pipeline by Eddingpharm, H2 2016 47

Pipeline by Eisai Co., Ltd., H2 2016 48

Pipeline by Eli Lilly and Company, H2 2016 50

Pipeline by Hutchison MediPharma Limited, H2 2016 51

Pipeline by Incyte Corporation, H2 2016 52

Pipeline by Johnson & Johnson, H2 2016 53

Pipeline by Kaken Pharmaceutical Co., Ltd., H2 2016 54

Pipeline by Les Laboratoires Servier SAS, H2 2016 55

Pipeline by Nobelpharma Co., Ltd., H2 2016 56

Pipeline by Novartis AG, H2 2016 57

Pipeline by Principia Biopharma Inc., H2 2016 58

Pipeline by Vichem Chemie Research Ltd., H2 2016 59

Dormant Projects, H2 2016 119

Dormant Projects (Contd..1), H2 2016 120

Dormant Projects (Contd..2), H2 2016 121

Discontinued Products, H2 2016 122

Discontinued Products (Contd..1), H2 2016 123

List of Figures

List of Figures

Number of Products under Development for, H2 2016 11

Number of Products under Development by Therapy Area, H2 2016 12

Number of Products under Development by Top 10 Indication, H2 2016 13

Comparative Analysis by Late Stage Development, H2 2016 15

Comparative Analysis by Early Stage Products, H2 2016 16

Assessment by Monotherapy/Combination Products, H2 2016 27

Number of Products by Mechanism of Actions, H2 2016 28

Number of Products by Stage and Mechanism of Actions, H2 2016 28

Number of Products by Routes of Administration, H2 2016 30

Number of Products by Stage and Routes of Administration, H2 2016 30

Number of Products by Molecule Types, H2 2016 32

Number of Products by Stage and Molecule Type, H2 2016 32

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports